Literature DB >> 2935737

The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients.

S W MacMahon, D E Wilcken, G J Macdonald.   

Abstract

We compared the effects of weight reduction, metoprolol, and placebo on M-mode echocardiographic measurements of the thickness and mass of the left ventricular wall in a 21-week, randomized controlled trial that enrolled 41 young, overweight patients with hypertension. At the end of the follow-up period, the patients in the weight-reduction group had lost an average of 8.3 kg, and their blood pressure had decreased by an average of 14/13 mm Hg, as compared with 12/8 mm Hg in the metoprolol group and 9/4 mm Hg in the placebo group. In the weight-reduction group, interventricular septal and posterior-wall thickness decreased by 14 percent and 11 percent, respectively, and left ventricular mass decreased by 20 percent (16 percent when adjusted for body-surface area). Decreases in interventricular septal and posterior-wall thickness and in left ventricular mass in the weight-reduction group were significantly greater than those in the placebo group. The changes in thickness of the interventricular septum and the left ventricular mass in the weight-reduction group were also greater than those in the metoprolol group. Changes in weight, independent of changes in blood pressure, were directly associated with changes in left ventricular mass. We conclude that weight reduction decreases left ventricular mass in overweight hypertensive patients and that control of obesity is important not only for the treatment of hypertension but also for the prevention of left ventricular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2935737     DOI: 10.1056/NEJM198602063140602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  47 in total

1.  Relationship between left ventricular mass and coronary artery disease in young adults: a single-center study using cardiac computed tomography.

Authors:  Jae Yong Cho; Joo Sung Sun; Young Keun Sur; Jin Sun Park; Doo Kyoung Kang
Journal:  Int J Cardiovasc Imaging       Date:  2015-10-01       Impact factor: 2.357

2.  Predictors of left ventricular dilatation in young adults (from the Bogalusa Heart Study).

Authors:  Showkat A Haji; Rifat Eralp Ulusoy; Dharmendrakumar A Patel; Sathanur R Srinivasan; Wei Chen; Patrice Delafontaine; Gerald S Berenson
Journal:  Am J Cardiol       Date:  2006-09-07       Impact factor: 2.778

3.  Weight control in managing hypertension.

Authors:  K A Conrad; J R Conrad; T C Fagan
Journal:  West J Med       Date:  1987-09

Review 4.  Regression of increased left ventricular mass by antihypertensives.

Authors:  C J Lavie; H O Ventura; F H Messerli
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

5.  Essential hypertension: when and how to initiate treatment.

Authors:  R W Swanson; R Spooner
Journal:  Can Fam Physician       Date:  1989-09       Impact factor: 3.275

Review 6.  Obesity. Part I--Pathogenesis.

Authors:  G A Bray; D S Gray
Journal:  West J Med       Date:  1988-10

7.  Effects of isolated obesity on systolic and diastolic left ventricular function.

Authors:  M Pascual; D A Pascual; F Soria; T Vicente; A M Hernández; F J Tébar; M Valdés
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

Review 8.  Left ventricular hypertrophy. Prevalence in older patients and management.

Authors:  E Paciaroni; A Fraticelli
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

9.  Impaired flow-mediated vasodilatation is associated with increased left ventricular mass in a multiethnic population. The Northern Manhattan Study.

Authors:  Takuya Hasegawa; Bernadette Boden-Albala; Kazuo Eguchi; Zhezhen Jin; Ralph L Sacco; Shunichi Homma; Marco R Di Tullio
Journal:  Am J Hypertens       Date:  2010-01-07       Impact factor: 2.689

10.  Effects of weight-reduction on obesity-associated diseases.

Authors:  Hermann Liebermeister
Journal:  Ger Med Sci       Date:  2003-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.